Publication | Closed Access

Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial

OncologyGastrointestinal OncologyColorectal CancerPathologyCancer TreatmentMedicineRadiation OncologyMolecular Oncology